Department of Structural Biology, Van Andel Institute, Grand Rapids, Michigan 49503, U.S.A.
Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI 49546, U.S.A.
Biochem J. 2021 Dec 10;478(23):4137-4149. doi: 10.1042/BCJ20210647.
Ornithine decarboxylase (ODC) is the rate-limiting enzyme for the synthesis of polyamines (PAs). PAs are oncometabolites that are required for proliferation, and pharmaceutical ODC inhibition is pursued for the treatment of hyperproliferative diseases, including cancer and infectious diseases. The most potent ODC inhibitor is 1-amino-oxy-3-aminopropane (APA). A previous crystal structure of an ODC-APA complex indicated that APA non-covalently binds ODC and its cofactor pyridoxal 5-phosphate (PLP) and functions by competing with the ODC substrate ornithine for binding to the catalytic site. We have revisited the mechanism of APA binding and ODC inhibition through a new crystal structure of APA-bound ODC, which we solved at 2.49 Å resolution. The structure unambiguously shows the presence of a covalent oxime between APA and PLP in the catalytic site, which we confirmed in solution by mass spectrometry. The stable oxime makes extensive interactions with ODC but cannot be catabolized, explaining APA's high potency in ODC inhibition. In addition, we solved an ODC/PLP complex structure with citrate bound at the substrate-binding pocket. These two structures provide new structural scaffolds for developing more efficient pharmaceutical ODC inhibitors.
鸟氨酸脱羧酶 (ODC) 是多胺 (PAs) 合成的限速酶。PA 是致癌代谢物,是增殖所必需的,因此抑制药物 ODC 被用于治疗增殖性疾病,包括癌症和传染病。最有效的 ODC 抑制剂是 1-氨基-2-氧代丙烷 (APA)。先前的 ODC-APA 复合物晶体结构表明,APA 以非共价键结合 ODC 和其辅因子吡哆醛 5-磷酸 (PLP),并通过与 ODC 底物鸟氨酸竞争结合催化位点来发挥作用。我们通过解析 APA 结合 ODC 的新晶体结构重新研究了 APA 结合和 ODC 抑制的机制,该结构的分辨率为 2.49 Å。该结构明确显示 APA 和 PLP 在催化位点之间形成了共价肟,我们通过质谱在溶液中证实了这一点。稳定的肟与 ODC 形成广泛的相互作用,但不能被代谢,这解释了 APA 对 ODC 抑制的高效力。此外,我们还解析了与结合在底物结合口袋的柠檬酸的 ODC/PLP 复合物结构。这两个结构为开发更有效的药物 ODC 抑制剂提供了新的结构支架。